Zacks Research Issues Positive Estimate for Amarin Earnings

Amarin Corporation PLC (NASDAQ:AMRN) – Zacks Research lifted their Q2 2026 earnings estimates for Amarin in a research note issued on Wednesday, June 17th. Zacks Research analyst Team now expects that the biopharmaceutical company will earn ($0.21) per share for the quarter, up from their previous forecast of ($0.22). Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Amarin’s current full-year earnings is ($1.15) per share. Zacks Research also issued estimates for Amarin’s Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.14) EPS, FY2027 earnings at ($0.89) EPS, Q1 2028 earnings at ($0.17) EPS and FY2028 earnings at ($0.69) EPS.

Several other analysts have also issued reports on AMRN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amarin in a research report on Monday, April 20th. Wall Street Zen cut shares of Amarin from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. One analyst has rated the stock with a Strong Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $12.00.

Amarin Stock Up 1.6%

AMRN stock opened at $16.03 on Friday. The company’s 50-day moving average price is $14.62 and its two-hundred day moving average price is $14.74. The firm has a market cap of $336.15 million, a P/E ratio of -24.66 and a beta of 0.82. Amarin has a 12 month low of $12.30 and a 12 month high of $20.90.

Institutional Investors Weigh In On Amarin

Hedge funds have recently modified their holdings of the company. Jones Financial Companies Lllp grew its position in Amarin by 449,522.1% during the 1st quarter. Jones Financial Companies Lllp now owns 1,811,977 shares of the biopharmaceutical company’s stock worth $815,000 after acquiring an additional 1,811,574 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Amarin by 192.6% during the third quarter. Millennium Management LLC now owns 132,391 shares of the biopharmaceutical company’s stock valued at $2,169,000 after purchasing an additional 87,147 shares in the last quarter. Waterfront Wealth Inc. boosted its stake in shares of Amarin by 82.8% during the fourth quarter. Waterfront Wealth Inc. now owns 142,540 shares of the biopharmaceutical company’s stock valued at $1,990,000 after purchasing an additional 64,580 shares in the last quarter. Jump Financial LLC acquired a new stake in shares of Amarin during the second quarter valued at about $623,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Amarin during the first quarter worth about $278,000. Institutional investors and hedge funds own 22.25% of the company’s stock.

More Amarin News

Here are the key news stories impacting Amarin this week:

• Positive Sentiment: Zacks Research upgraded Amarin to Strong-Buy, which is a supportive signal for sentiment and may be contributing to the stock’s recent strength. Zacks.com
• Positive Sentiment: Analysts raised earnings estimates for several periods, including FY2026, FY2027, and some quarterly forecasts, suggesting a slightly better outlook for Amarin’s loss trajectory over time. MarketBeat AMRN
• Neutral Sentiment: Not all revisions were positive: Zacks also trimmed some near-term estimates, including Q3 2026, Q4 2026, and Q1 2028 EPS, which tempers the bullish message. MarketBeat AMRN
• Negative Sentiment: The company is still expected to post losses across the forecast period, with consensus full-year earnings remaining negative, so fundamentals are not yet showing a profit turnaround. MarketBeat AMRN

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.